Price Don’t Lie: Aradigm Corporation Sets All-Time Low; Strong Momentum for Sellers

Price Don't Lie: Aradigm Corporation Sets All Time Low; Strong Momentum for Sellers

The stock of Aradigm Corporation (NASDAQ:ARDM) reached all time low today, Dec, 1 and still has $2.34 target or 3.00% below today’s $2.41 share price. This indicates more downside for the $36.31 million company. This technical setup was reported by If the $2.34 PT is reached, the company will be worth $1.09 million less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only. About 645,005 shares traded hands or 2908.70% up from the average. Aradigm Corporation (NASDAQ:ARDM) has risen 9.85% since April 28, 2016 and is uptrending. It has outperformed by 3.93% the S&P500.

Analysts await Aradigm Corporation (NASDAQ:ARDM) to report earnings on March, 21.

According to Zacks Investment Research, “Aradigm Corp. is a leading developer of advanced pulmonary drug delivery systems for the treatment of systemic conditions as well as lung diseases. Their hand-held AERx platform is being designed for the rapid and reproducible delivery of a wide range of pharmaceutical drugs and biotech compounds via the lung.”

Insitutional Activity: The institutional sentiment decreased to 0.8 in 2016 Q2. Its down 0.45, from 1.25 in 2016Q1. The ratio fall, as 3 funds sold all Aradigm Corporation shares owned while 1 reduced positions. 3 funds bought stakes while 2 increased positions. They now own 5.45 million shares or 0.52% less from 5.48 million shares in 2016Q1.
Blackrock Fund accumulated 1,934 shares or 0% of the stock. First Eagle Investment Mngmt holds 0.04% of its portfolio in Aradigm Corporation (NASDAQ:ARDM) for 3.85M shares. The New York-based Tower Rech Ltd Liability Corp (Trc) has invested 0% in Aradigm Corporation (NASDAQ:ARDM). Evercore Wealth Management Lc has 2 shares for 0% of their US portfolio. Focused Wealth Mngmt Inc holds 0% of its portfolio in Aradigm Corporation (NASDAQ:ARDM) for 2 shares. Acadian Asset Mngmt Ltd Liability Corp has 1,584 shares for 0% of their US portfolio. Goldman Sachs Gp last reported 16,385 shares in the company. Fmr Ltd Company, a Massachusetts-based fund reported 168,740 shares. Ladenburg Thalmann Financial Serv accumulated 2 shares or 0% of the stock. Jacobs Levy Equity reported 14,800 shares or 0% of all its holdings. Point72 Asset L P has invested 0.01% of its portfolio in Aradigm Corporation (NASDAQ:ARDM). The New Jersey-based Blackrock Inv Management Limited Com has invested 0% in Aradigm Corporation (NASDAQ:ARDM). Deutsche Bancorp Ag accumulated 61,538 shares or 0% of the stock. Bancorporation Of America De holds 0% of its portfolio in Aradigm Corporation (NASDAQ:ARDM) for 28 shares. Livingston Group Asset Management Communications (Operating As Southport Management) holds 0% or 1,000 shares in its portfolio.

Insider Transactions: Since October 4, 2016, the stock had 0 insider purchases, and 1 sale for $2,859 net activity. $2,859 worth of Aradigm Corporation (NASDAQ:ARDM) shares were sold by Froehlich Juergen Kurt.

More important recent Aradigm Corporation (NASDAQ:ARDM) news were published by: which released: “Aradigm Corp. (ARDM) Announces Mixed Results from Two Pulmaquin Phase 3s in …” on December 01, 2016, also published article titled: “Aradigm Corp. NASDAQ: ARDM”, published: “Aradigm Corporation Announces First Closing of Private Placement Offering of …” on April 26, 2016. More interesting news about Aradigm Corporation (NASDAQ:ARDM) was released by: and their article: “6 Reasons Aradigm Corporation Is An Excellent Risk Vs. Reward Opportunity” with publication date: August 08, 2014.

ARDM Company Profile

Aradigm Corporation, incorporated on January 30, 1991, is a specialty pharmaceutical firm focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. It is focused on commercializing its products in the United States, European Union (EU), Japan and China. The Company’s lead product candidate is Pulmaquin inhaled ciprofloxacin, which is in Phase III clinical trials. The Firm offers AERx pulmonary drug delivery platform and other technologies. The Company’s partnered programs under development include Inhaled Ciprofloxacin. The Firm is also engaged in developing Smoking Cessation Therapy (ARD-1600 Inhaled Nicotine). The Firm is focused on inhaled nicotine product utilizing its AERx delivery system that is focused on addressing the acute craving for cigarettes and, through gradual reduction of the peak nicotine levels, could wean-off patients from cigarette smoking and from the nicotine addiction.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment